样式: 排序: IF: - GO 导出 标记为已读
-
Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Mandar Sudhir Paradkar,Neeta Nitin Pradhan,Subramanyam Balaji,Sanjay Narayan Gaikwad,Amol Chavan,Sujata Nagnath Dharmashale,Tushar Sahasrabudhe,Rahul Lokhande,Sona Anil Deshmukh,Madhusudan Barthwal,Sachin Atre,Swapnil Suresh Raskar,Trupti Uday Sawant,Akshay N Gupte,ArjunLal Kakrani,Jonathan Golub,Chandrasekaran Padmapriyadarsini,Amita Gupta,Nikhil Anil Gupte,Vidya Mave
Rationale: Earlier biomarkers of pulmonary tuberculosis (PTB) treatment outcomes are critical to monitor shortened anti-TB treatment (ATT). Objectives: To identify early microbiologic markers of unfavorable TB treatment outcomes. Methods: We performed a subanalysis of 2 prospective TB cohort studies conducted from 2013 to 2019 in India. We included participants aged ⩾18 years who initiated 6-month
-
All the Lonely People: Social Isolation and Loneliness in Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Lauren E Ferrante,Andrew B Cohen
-
The Price Is Right: Cost-Effectiveness of Long-Term Azithromycin for Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Brice Taylor,Stephen Chiang,Stephanie Taylor
-
A Crystal Ball for Hypoxia in Fibrotic Interstitial Lung Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Shweta Sood,John S Kim
-
The Relevance of Dysautonomia on Exercise Responses. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Guilherme Ward Leite,Natalia de Alcantara Zimmermann,José Leonidas Alves,João Marcos Salge,André Luis Pereira de Albuquerque
-
Do American Thoracic Society and European Respiratory Society Journals Have a Role in Promoting Official American Thoracic Society and European Respiratory Society Standards? Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Martin R Miller,Sanja Stanojevic,Brian L Graham
-
Does Obstructive Sleep Apnea Treatment Influence Lipoprotein (a) Concentrations? Data from the TREATOSA-MS Clinical Trial. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Sara Q C Giampá,Luciana G Viana,Karina H M Cardozo,Thiago A Macedo,Sofia F Furlan,Lunara S Freitas,Luiz A Bortolotto,Geraldo Lorenzi-Filho,Luciano F Drager
-
Educational Attainment and Loss to Follow-up in a Quebec Lung Cancer Screening Pilot Program. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Everglad Mugutso,Charlotte Besson,Rola Hamed,Francine Noel,Jana Taylor,Anne Gonzalez,Nicole Ezer
-
Effect of Respiratory Viral Panel Adoption on Antibiotic Use in Ventilated Patients. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Jacqueline Dinh,Chad F Hinkle,Anica C Law,Allan J Walkey,Nicholas A Bosch
Rationale: Rapid respiratory viral panel (RVP) testing has become widely used to aid in the diagnosis and treatment of acute respiratory failure. However, the impact of RVP on antibiotic stewardship in critically ill patients is unclear. Objectives: To assess if adoption of RVP testing at hospitals was associated with changes in antibiotic duration in intensive care unit patients receiving invasive
-
Sleep-disordered Breathing and Inpatient Outcomes in Nonsurgical Patients: Analysis of the Nationwide Inpatient Cohort. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Anna M May
Rationale: Sleep-disordered breathing (SDB) is associated with increased complications and length of stay (LOS) after surgery. SDB-related adverse consequences for nonsurgical admissions are not well defined. Objectives: Evaluate associations between SDB and subtypes and LOS, cost, and mortality in nonsurgical patients. Methods: This retrospective cohort analysis used adult nonsurgical admissions from
-
Redefining Comorbid Insomnia and Sleep Apnea: The Association of Sleep Breathing Impairment and Insomnia with Incident Diabetes. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Junwei Guo,Susan Redline,Katie L Stone,Yi Xiao
Rationale: Obstructive sleep apnea (OSA) is a prevalent sleep disorder that is frequently comorbid with insomnia and often accompanied by metabolic diseases such as type 2 diabetes. Although the apnea-hypopnea index (AHI) is currently the diagnostic criterion for gauging the severity of OSA, the AHI has not consistently predicted incident diabetes. Objectives: To test whether a combined insomnia-OSA
-
A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Don B Sanders,Traci M Bartz,Edith T Zemanick,Jordana E Hoppe,Karen D Hinckley Stukovsky,Jonathan D Cogen,Lisa Bendy,Sharon McNamara,Erika Enright,Noah A Kime,Richard A Kronmal,Todd C Edwards,Wayne J Morgan,Margaret Rosenfeld
Rationale: Despite the high prevalence and clear morbidity of cystic fibrosis (CF) pulmonary exacerbations (PEx), there have been no published clinical trials of outpatient exacerbation management. Objectives: To assess the feasibility of a pediatric clinical trial in which treatment of mild PEx is assigned randomly to immediate oral antibiotics or tailored therapy (increased airway clearance alone
-
Regional Variation in Pulmonary Arterial Hypertension in the United States: The Pulmonary Hypertension Association Registry. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-12-01 Connor Fling,Teresa De Marco,Noah A Kime,Matthew R Lammi,Laura J Oppegard,John J Ryan,Corey E Ventetuolo,R James White,Roham T Zamanian,Peter J Leary
Rationale: Pulmonary arterial hypertension (PAH) is a heterogeneous disease within a complex diagnostic and treatment environment. Other complex heart and lung diseases have substantial regional variation in characteristics and outcomes; however, this has not been previously described in PAH. Objectives: To identify baseline differences between U.S. census regions in the characteristics and outcomes
-
Association between Patient Race and Ethnicity and Use of Invasive Ventilation in the United States of America. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-29 Fred M Abdelmalek,Federico Angriman,Julie Moore,Kuan Liu,Lisa Burry,Laleh Seyyed-Kalantari,Sangeeta Mehta,Judy Gichoya,Leo Anthony Celi,George Tomlinson,Michael Fralick,Christopher J Yarnell
RATIONALE Outcomes for people with respiratory failure in the USA vary by patient race and ethnicity. Invasive ventilation is an important treatment initiated based on expert opinion. It is unknown whether use of invasive ventilation varies by patient race and ethnicity. OBJECTIVE To measure (1) the association between patient race and ethnicity and the use of invasive ventilation and (2) the change
-
Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower FEV1 after Elexacaftor/Tezacaftor/Ivacaftor. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-29 David Nichols,Alex Gifford,Renee Russell,Katherine Odem-Davis,Julia Young,Rodolfo Amaro-Galvez,Joanne Billings,Zubin Mukadam,Nicole Mayer-Hamblett
-
It's Time for Health Professionals to Break the Climate Taboo. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-29 Alexander S Rabin
-
Comparative Effectiveness of Supine-Avoidance versus Continuous Positive Airway Pressure for Treating Supine-isolated Sleep Apnea. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-28 Matthew M Rahimi,Andrew Vakulin,R Doug McEvoy,Maree Barnes,Stephen J Quinn,Jeremy D Mercer,Amanda O'Grady,Nick A Antic,Peter G Catcheside
RATIONALE Around 20-35% of obstructive sleep apnoea (OSA) patients show supine-isolated OSA, where supine sleep avoidance could be an effective therapy. However, traditional supine discomfort-based methods show poor tolerance and compliance to treatment, so cannot be recommended. Supine-alarm devices show promise, but evidence to support favourable adherence to treatment and effectiveness at reducing
-
Cognitive and Emotional Responses to COPD Exacerbations and Patterns of Care Seeking. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-15 Emily R Locke,Rachel M Thomas,Tracy L Simpson,John C Fortney,Catherine Battaglia,Ranak B Trivedi,Joseph Gylys-Colwell,Erik R Swenson,Jeffrey D Edelman,Vincent S Fan
RATIONALE Cognitive and emotional responses associated with care seeking for COPD exacerbations are not well understood. OBJECTIVES We sought to define care seeking profiles based on whether and when US Veterans seek care for COPD exacerbations and compare cognitive and emotional responses to exacerbation symptoms across the profiles. METHODS This study analyzes data from a 1-year prospective observational
-
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-14 Christina S Thornton,Lindsay J Caverly,Linda M Kalikin,Lisa A Carmody,Scott McClellan,William LeBar,Don B Sanders,Natalie E West,Christopher H Goss,Patrick A Flume,Sonya L Heltshe,Donald R VanDevanter,John J LiPuma
RATIONALE Rates of viral respiratory infection (VRI) are similar in people with cystic fibrosis (CF) and the general population; however, the associations between VRI and CF pulmonary exacerbations (PEx) require further elucidation. OBJECTIVES To determine VRI prevalence during CF PEx and evaluate associations between VRI, clinical presentation, and treatment response. METHODS The Standardized Treatment
-
Quality of Life Bronchiectasis Respiratory Symptom Predicts the Risk of Exacerbations in Adults with Bronchiectasis: A Prospective Observational Study. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-14 Yong-Hua Gao,Hui-Zhen Zheng,Hai-Wen Lu,Yuan-Yuan Li,Yun Feng,Shu-Yi Gu,Xiao-Li Sun,Bei Mao,Jiu-Wu Bai,Shuo Liang,Ke-Bin Cheng,Jian-Xiong Li,Ai Ge,Man-Hui Li,Jia-Wei Yang,Lu Bai,Han-Yu Yu,Jie-Ming Qu,Jin-Fu Xu
RATIONALE The relationship between symptoms, measured using a validated disease-specific questionnaire, and longitudinal exacerbation risk has not been demonstrated in bronchiectasis. OBJECTIVES The aim of this study is to investigate whether baseline symptoms, assessed using the Quality of Life-Bronchiectasis-Respiratory Symptom Scale (QoL-B-RSS) and its individual component scores, could predict
-
Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective US Insurance Claims Study. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-14 Annika Åstrand,Steven J Kiddle,Rohith Siva Ganesh Mudedla,Sanchita Porwal,Kaushik Chafekar,Shubh Agrawal,Carlos Seminario,James D Chalmers,Ioannis Psallidas
RATIONALE Bronchiectasis is a chronic, progressive disease of bronchial dilation, inflammation, and scarring leading to impaired mucociliary clearance and increased susceptibility to infection. Identified causes include previous severe respiratory infections. A small, single-center UK study demonstrated a reduction in bronchiectasis exacerbations during the first year of the COVID-19 pandemic. No studies
-
Neighborhood Health and Outcomes in Idiopathic Pulmonary Fibrosis. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-14 Alison M DeDent,Harold R Collard,Neeta Thakur
RATIONALE Living in a disadvantaged neighborhood has been associated with worse survival in idiopathic pulmonary fibrosis (IPF), however prior studies have only examined the impact of neighborhood health on outcomes in IPF as a composite measure. OBJECTIVES Investigate the association between neighborhood health and disease severity, measured by pulmonary function at presentation, and death in follow-up
-
OPTIMA: An Open-Label, Non-comparative Pilot Trial of Inhaled Molgramostim in Pulmonary Nontuberculous Mycobacterial Infection. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-10 Rachel M Thomson,Michael R Loebinger,Andrew J Burke,Lucy C Morgan,Grant W Waterer,Cecilia Ganslandt
RATIONALE Inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) has been proposed as a potential immunomodulatory treatment for nontuberculous mycobacterial (NTM) infection. OBJECTIVES This open label, non-comparative pilot trial investigated the efficacy and safety of inhaled GM-CSF (molgramostim nebulizer solution) in patients with predominantly treatment-refractory pulmonary NTM (M.
-
Long-Term Home Non-Invasive Ventilation and Exacerbations of COPD: A 'Real-World' Study. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-10 Jeffrey Marciniuk,Michael Frohlich,Jean Bourbeau,Marta Kaminska,Isabelle Drouin,Isabelle Ouellet,Bryan Ross
-
Sustained Clinical Benefits of Spiration Valve System in Severe Emphysema Patients: 24-Month Follow-Up of EMPROVE. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-10 Gerard J Criner,Jorge M Mallea,Muhanned Abu-Hijleh,Ashutosh Sachdeva,Ravi Kalhan,Christopher A Hergott,Donald R Lazarus,Richard A Mularski,Karel Calero,Michael F Reed,Stephanie Nsiah-Dosu,David Himes,Hiroshi Kubo,C Matthew Kinsey,Adnan Majid,D Kyle Hogarth,Philip V Kaplan,Amy Hajari Case,Samir S Makani,Tze-Ming Chen,Antoine Delage,Michael Zgoda,Ray W Shepherd
RATIONALE Follow-up of emphysema patients treated with endobronchial valves is limited to 3-12 months after treatment in prior reports. To date, no comparative data exist between treatment and controls with a longer follow-up. OBJECTIVE To assess the durability of the Spiration® Valve System (SVS) in patients with severe heterogeneous emphysema over a 24-month period. METHODS EMPROVE, a multicenter
-
Racial Differences in 1-Year Mortality after Hospitalization for Chronic Obstructive Pulmonary Disease in the United States. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-09 Snigdha Jain,Aruna Priya,Penelope Pekow,Kerry Spitzer,Allan Walkey,Ijeoma Opara,Harlan M Krumholz,Peter K Lindenauer
RATIONALE One-quarter of Medicare beneficiaries hospitalized for chronic obstructive pulmonary disease die within a year. While overall mortality is higher among chronic obstructive pulmonary disease patients of White race, racial and ethnic differences in the vulnerable period following hospitalization are unknown. OBJECTIVES To determine the association between race and ethnicity and mortality following
-
Loop Gain as a Predictor of Blood Pressure Response in Patients Treated for Obstructive Sleep Apnea. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-08 Christopher N Schmickl,Jeremy E Orr,Scott A Sands,Raichel M Alex,Ali Azarbarzin,Lana McGinnis,Stephanie White,Diego R Mazzotti,Brandon Nokes,Robert L Owens,Daniel J Gottlieb,Atul Malhotra
Rationale: Randomized trials have shown inconsistent cardiovascular benefits from obstructive sleep apnea (OSA) therapy. Intermittent hypoxemia can increase both sympathetic nerve activity and loop gain ("ventilatory instability"), which may thus herald cardiovascular treatment benefit. Objectives: Test the hypothesis that loop gain predicts changes in 24h-mean blood pressure (Δ24h-MBP) in response
-
Impact of Reducing Time-to-Antibiotics on Sepsis Mortality, Antibiotic Use, and Adverse Events. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-07 John P Donnelly,Sarah M Seelye,Patricia Kipnis,Brenda M McGrath,Theodore J Iwashyna,Jason Pogue,Makoto Jones,Vincent X Liu,Hallie C Prescott
RATIONALE Shorter time-to-antibiotics is lifesaving in sepsis, but programs to hasten antibiotic delivery may increase unnecessary antibiotic use and adverse events. OBJECTIVE We sought to estimate both benefits and harms of shortening time-to-antibiotics for sepsis. METHODS Simulation study using a cohort of 1,559,523 hospitalizations via emergency department with ≥2 systemic inflammatory response
-
Accelerating Action: Roadmap for the American Thoracic Society to Address Oppression and Health Inequity in Pulmonary and Critical Care Medicine. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-07 Sande O Okelo,Christopher F Chesley,Isaretta Riley,Alejandro A Diaz,Karen Collishaw,Lynn M Schnapp,Neeta Thakur
-
Risks of Zolpidem among Patients with Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-02 Jason M Castaneda,Travis Hee Wai,Laura J Spece,Kevin I Duan,Aristotle Leonhard,Matthew F Griffith,Robert Plumley,Brian N Palen,Laura C Feemster,David H Au,Lucas M Donovan
RATIONALE Non-benzodiazepine benzodiazepine receptor agonists (NBZRA, e.g., zolpidem) are frequently used to treat insomnia among patients with chronic obstructive pulmonary disease (COPD). However, multiple observational studies find that patients with COPD who are prescribed NBZRAs have greater risks for mortality and respiratory complications than patients without such prescriptions. Without an
-
Understanding Sleep and Circadian Disruption in the Intensive Care Unit. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Fernando G Zampieri,M Elizabeth Wilcox
-
Refractory Hypoxemia in Acute-on-Chronic Submassive Pulmonary Embolism. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Sarah Gorgis,Benjamin Yuhwei Yang,Michael Zhen-Yu Tong,Joanna Ghobrial,Mohammed J Al-Jaghbeer
-
Pulse Oximetry Misclassifies Need for Long-Term Oxygen Therapy in Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Ashraf Fawzy,Robert A Wise
-
Unchanging Mortality from Pulmonary Embolism in the United States. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Yon K Sung,Jeffrey A Kline
-
Reading between the Beats: A Curious Case of Increased Periodic Breathing. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Michael L Setteducato,Emily M Beck,Susheela Hadigal
-
A Hybrid Effectiveness/Implementation Clinical Trial of Adherence to Long-Term Oxygen Therapy for Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Valentin Prieto-Centurion,Kristen E Holm,Richard Casaburi,Janos Porszasz,Sanjib Basu,Nina E Bracken,Richard Gallardo,Vanessa Gonzalez,Sai D Illendula,Robert A Sandhaus,Jamie L Sullivan,Linda J Walsh,Lynn B Gerald,Jerry A Krishnan
Rationale: Interventions to promote adherence to long-term oxygen therapy (LTOT) in chronic obstructive pulmonary disease (COPD) are needed. Objectives: To examine the real-world effectiveness of phone-based peer coaching on LTOT adherence and other outcomes in a pragmatic trial of patients with COPD. Methods: In a hybrid effectiveness/implementation pragmatic trial, patients were randomized to receive
-
"Fighting the Ventilator": Abandoning Exclusionary Violence Metaphors in the Intensive Care Unit. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Shannen Kim,Samuel McGowan,Teva Brender,David Bamman,Julien Cobert
-
Adverse Events during Adulthood, Child Maltreatment, and Asthma among British Adults in the UK Biobank. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Yueh-Ying Han,Wei Chen,Erick Forno,Juan C Celedón
Rationale: Intimate partner violence and child maltreatment have been separately associated with asthma in adults. No study has concurrently examined of adulthood adverse events (including, but not limited to, intimate partner violence) and child maltreatment on asthma in adults. Objectives: To concurrently examine of adulthood adverse events and child maltreatment on asthma in adults. Methods: This
-
Associations of Histamine Metabolites with Disease Severity and Mortality in Pulmonary Arterial Hypertension. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Brandon S Peplinski,Jonathan Buber,Sina A Gharib,Hongyang Pi,Daniel Raftery,Peter J Leary
-
Supplemental Oxygen Therapy in Interstitial Lung Disease: A Narrative Review. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Kristopher P Clark,Howard B Degenholtz,Kathleen O Lindell,Daniel J Kass
Patients with interstitial lung diseases (ILD) often have hypoxemia at rest and/or with exertion, for which supplemental oxygen is commonly prescribed. The number of patients with ILD who require supplemental oxygen is unknown, although estimates suggest it could be as much as 40%; many of these patients may require high-flow support (>4 L/min). Despite its frequent use, there is limited evidence for
-
Relative Loss of Small Pulmonary Vessels on Imaging and Risk of Recurrence of Resected Lung Adenocarcinoma. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Andrew J Synn,Tess D Litchman,Constance De Margerie-Mellon,Alexander A Bankier,Farbod N Rahaghi,George R Washko,Raúl San José Estépar,Paul A VanderLaan,Mary B Rice
-
Adoption of a Novel Vasopressor Agent in Critically Ill Adults. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Emily A Vail,Nicholas A Bosch,Anica C Law,Hayley B Gershengorn,Hannah Wunsch,Allan J Walkey
-
Elexacaftor/Tezacaftor/Ivacaftor Improves Bronchial Artery Dilatation Detected by Magnetic Resonance Imaging in Patients with Cystic Fibrosis. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Lena Wucherpfennig,Simon M F Triphan,Sabine Wege,Hans-Ulrich Kauczor,Claus P Heussel,Olaf Sommerburg,Mirjam Stahl,Marcus A Mall,Monika Eichinger,Mark O Wielpütz
Rationale: Magnetic resonance imaging (MRI) detects improvements in mucus plugging and bronchial wall thickening, but not in lung perfusion in patients with cystic fibrosis (CF) treated with elexacaftor/tezacaftor/ivacaftor (ETI). Objectives: To determine whether bronchial artery dilatation (BAD), a key feature of advanced lung disease, indicates irreversibility of perfusion abnormalities and whether
-
Sleep Testing and Mortality in a Propensity-matched Cohort of Patients with Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Lucas M Donovan,Travis Wai,Laura J Spece,Kevin I Duan,Matthew F Griffith,Aristotle Leonhard,Robert Plumley,Sophia A Hayes,Fernando Picazo,Kristina Crothers,Vishesh K Kapur,Brian N Palen,David H Au,Laura C Feemster
Rationale: Many advocate the application of propensity-matching methods to real-world data to answer key questions around obstructive sleep apnea (OSA) management. One such question is whether identifying undiagnosed OSA impacts mortality in high-risk populations, such as those with chronic obstructive pulmonary disease (COPD). Objectives: Assess the association of sleep testing with mortality among
-
Longitudinal Changes and Association of Respiratory Symptoms with Preserved Ratio Impaired Spirometry (PRISm): The Nagahama Study. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Mariko Kogo,Susumu Sato,Shigeo Muro,Hisako Matsumoto,Natsuko Nomura,Tsuyoshi Oguma,Hironobu Sunadome,Tadao Nagasaki,Kimihiko Murase,Takahisa Kawaguchi,Yasuharu Tabara,Fumihiko Matsuda,Kazuo Chin,Toyohiro Hirai
Rationale: Subjects with preserved ratio impaired spirometry (PRISm) experience increased respiratory symptoms, although they present heterogeneous characteristics. However, the longitudinal changes in these symptoms and respiratory function are not well known. Objectives: To investigate PRISm from the viewpoint of respiratory symptoms in a longitudinal, large-scale general population study. Methods:
-
Sex, Racial, and Geographic Disparities in Pulmonary Embolism-related Mortality Nationwide. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Mohamed Zghouzi,Hunter Mwansa,Supriya Shore,Syed N Hyder,Neil Kamdar,Victor M Moles,Geoffrey D Barnes,James Froehlich,Vallerie V Mclaughlin,Timir K Paul,Kenneth Rosenfield,Jay Giri,Brahmajee K Nallamothu,Vikas Aggarwal
Rationale: Acute pulmonary embolism is a leading cause of cardiovascular death. There are limited data on the national mortality trends from pulmonary embolism. Understanding these trends is crucial for addressing the mortality and associated disparities associated with pulmonary embolism. Objectives: To analyze the national mortality trends related to acute pulmonary embolism and determine the overall
-
Exhaled Volatile Organic Compound Profiles Differ between Children with Primary Ciliary Dyskinesia and Cystic Fibrosis. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Elias Seidl,Johann-Christoph Licht,Wallace B Wee,Martin Post,Felix Ratjen,Hartmut Grasemann
-
Hypoxic Burden Based on Automatically Identified Desaturations Is Associated with Adverse Health Outcomes. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Neda Esmaeili,Gonzalo Labarca,Wen-Hsin Hu,Daniel Vena,Ludovico Messineo,Laura Gell,Mohammadreza Hajipour,Luigi Taranto-Montemurro,Scott A Sands,Susan Redline,Andrew Wellman,Mohammadreza Sehhati,Ali Azarbarzin
Rationale: Recent studies have shown that sleep apnea-specific intermittent hypoxemia quantified by the hypoxic burden (HB) predicted cardiovascular disease (CVD)-related mortality in community-based and clinical cohorts. Calculation of HB is based on manual scoring of hypopneas and apneas, which is time-consuming and prone to interscorer variability. Objective: To validate a novel method to quantify
-
The Impact of SARS-CoV-2 Infection on Symptom Control and Lung Function in Children with Asthma. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-11-01 Kristina Gaietto,Nicholas Bergum,Natalia Acevedo-Torres,Oliver Snyder,Leigh Anne DiCicco,Gabriella Butler,Sherry Rauenswinter,Jennifer Iagnemma,David Wolfson,Traci M Kazmerski,Erick Forno
Rationale: Little is known about the long-term impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on children with asthma. Objectives: To determine whether SARS-CoV-2 infection affects symptom control and lung function in children with asthma. Methods: Using data from clinical registries and the electronic health record, we conducted a prospective case-control study of
-
Adverse Health Impacts of Outdoor Air Pollution, including from Wildland Fires, in the United States: "Health of the Air," 2018-2020. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-31 Kevin Cromar,Laura Gladson,Julia Gohlke,Yunyao Li,Daniel Tong,Gary Ewart
RATIONALE Adverse health impacts from outdoor air pollution occur across the U.S., but the magnitude of these impacts varies widely by geographic region. Ambient pollutant concentrations, emission sources, baseline health conditions, and population sizes and distributions are all important factors that need to be taken into account to quantify local health burdens. OBJECTIVE To determine health impacts
-
Disease Manifestations in Siblings with Primary Ciliary Dyskinesia. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-30 Dvir Gatt,Michelle Shaw,Jacob McCoy,Fiona Kritzinger,Melinda Solomon,Sharon Dell,Felix Ratjen
-
Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena: An Official American Thoracic Society Report. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-30 Milica Vukmirovic,Kambez H Benam,Jason J Rose,Scott Turner,Chelsea M Magin,David Lagares,Alan H Cohen,Naftali Kaminski,Jeremy A Hirota,Toby M Maher,Melanie Königshoff,Rama K Mallampalli,Dean Sheppard,Robert Tarran,Richard H Gomer,Nicholas J Kenyon,David Morris,Silke Hobbie,S Vamsee Raju,Irina Petrache,Timothy Watkins,Rishav Kumar,Wilbur A Lam,Todd Sherer,Louise Hecker
"Translational Medicine" has been a buzzword for over two decades. The concept was intended to be lofty, to reflect a new "bench-to-bedside" approach to basic and clinical research that would bridge fields, close gaps, accelerate innovation, and shorten the time and effort it takes to bring novel technologies from basic discovery to clinical application. Has this approach been successful and lived
-
Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016-2022. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-25 Divya A Shankar,Finn Hawkins,Konstantinos-Dionysios Alysandratos,Kevin C Wilson,Allan Walkey,Nicholas A Bosch,Anica C Law
-
Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-25 Thomas Radtke,Don S Urquhart,Julia Braun,Peter J Barry,Ian Waller,Nicole Petch,Meir Mei-Zahav,Mordechai R Kramer,Thong Hua-Huy,Anh Tuan Dinh-Xuan,J Alastair Innes,Sara McArthur,Aleksandar Sovtic,Bojana Gojsina,Samuel Verges,Tanguy de Maat,Lisa Morrison,Jamie Wood,Samantha Crute,Craig A Williams,Owen W Tomlinson,Ronen Bar-Yoseph,Alexandra Hebestreit,Bradley S Quon,Eugenie Kwong,Zoe L Saynor,Adam J Causer
Rationale: Cardiopulmonary exercise testing (CPET) provides prognostic information in cystic fibrosis (CF); however, its prognostic value for patients with advanced CF lung disease (ACFLD) is unknown. Objectives: To determine the prognostic value of CPET on the risk of death or lung transplant (LTX) within 2-years. Methods: We retrospectively collected data from 20 CF centers in Asia, Australia, Europe
-
Lung Allocation Score Exceptions in Persons with Cystic Fibrosis Undergoing Lung Transplant. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-25 Omar F Bayomy,Miranda C Bradford,Tijana Milinic,Siddhartha G Kapnadak,Eric D Morrell,Erika D Lease,Christopher H Goss,Kathleen J Ramos
RATIONALE Lung transplant can extend life for individuals with advanced cystic fibrosis (CF). Until March, 2023 the United States used the lung allocation score (LAS) to determine transplant priority. Certain clinical events/attributes ("risk events") that were not included in the LAS (e.g., massive hemoptysis) are relatively common and prognostically important in CF, and may prompt an exception request
-
Effects of Weight Change and Weight Cycling on Lung Function in Overweight and Obese Adults. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-23 Kevin De Soomer,Hilde Vaerenberg,Joost Weyler,Evelyn Pauwels,Hilde Cuypers,Johan Verbraecken,Ellie Oostveen
RATIONALE Epidemiological studies have reported on the detrimental effects on lung function after natural, thus limited, weight gain in time in unselected populations. Studies on bariatric surgery, on the other hand, have indicated large improvements of lung function after substantial weight loss. OBJECTIVE To study the associations between a profound weight loss or gain and pulmonary function within
-
Diffusing Capacity as a Predictor of Hospitalizations in a Clinical Cohort of Chronic Obstructive Pulmonary Disease. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-23 Aparna Balasubramanian,Andrew S Gearhart,Nirupama Putcha,Ashraf Fawzy,Anil Singh,Robert A Wise,Nadia N Hansel,Meredith C McCormack
RATIONALE Chronic Obstructive Pulmonary Disease(COPD) hospitalizations are a major burden on patients. Diffusing capacity (DLCO) is a potential predictor that has not been studied in large cohorts. OBJECTIVE This study used electronic health record data to evaluate whether clinically-obtained DLCO predicts COPD hospitalizations. METHODS We performed time-to-event analyses of individuals with COPD and
-
Statin Use and Reduced Risk of Pneumonia in Melioidosis Patients: A Lung-Specific Statin Association. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-20 Taylor D Coston,Shelton W Wright,Rungnapa Phunpang,Adul Dulsuk,Ekkachai Thiansukhon,Seksan Chaisuksant,Kittisak Tanwisaid,Somchai Chuananon,Chumpol Morakot,Narongchai Sangsa,Sunee Chayangsu,Wirayut Silakun,Noppol Buasi,Ploenchan Chetchotisakd,Nicholas P J Day,Ganjana Lertmemongkolchai,Narisara Chantratita,T Eoin West
RATIONALE HMG-CoA reductase inhibitor (statin) use is associated with a lower risk of incident pneumonia and, less robustly, with non-pulmonary infections. Whether statin use is associated with a lower risk of pneumonia compared to other clinical presentations of infection with the same pathogen is unknown. OBJECTIVES To assess whether pre-admission statin use is associated with a lower risk of pneumonia
-
Summary for Clinicians-Clinical Practice Guideline for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-19 Tanzib Hossain,Sydney B Montesi,Elizabeth R Volkmann,Carey C Thomson,Joseph K Ruminjo,Richard M Silver,Marya Ghazipura,Ganesh Raghu
-
Temporal Trends in Use of Opioids for Patients with Acute Respiratory Failure following "Analgesia-First" Sedation Guidelines. Ann. Am. Thorac. Soc. (IF 8.3) Pub Date : 2023-10-17 Nicholas A Bosch,Laura C Myers,S Reza Jafarzadeh,Hannah Wunsch,Jennifer P Stevens,Vincent X Liu,Allan J Walkey